Moleculomics is a life science technology company focused on genome scale in silico modelling of protein structure, ligand docking and protein-protein interactions, serving the pharmaceutical, health and biotech sectors. The company develops computational technologies for drug discovery, toxicity screening and precision medicine, which are based on application of artificial intelligence to genome scale molecular structure and interaction data, resulting in platform technologies and a wide range of services that are globally unique in their extent and algorithmic reach. R&D is built on a track record of structural modelling research featured in over 70 journal publications. In recent years, Moleculomics has been delivering commercial R&D programs including both Hit-to-Lead and toxicity screening work in prestigious projects with a number of global partners, resulting in an unrivalled range of in silico technologies. http://www.moleculomics.com http://www.Human3DProteome.com